Letters
MS risk sharing scheme
Some clarification needed
BMJ 2010; 341 doi: https://doi.org/10.1136/bmj.c3589 (Published 07 July 2010) Cite this as: BMJ 2010;341:c3589
- Richard G Richards, assistant director of public health1
- 1NHS Derbyshire County, Babington Hospital, Belper, Derbyshire DE56 1WH
- richard.richards{at}derbyshirecountypct.nhs.uk
With reference to the use of interferon beta in multiple sclerosis,1 Betaferon is already off patent, and there has been an unholy scramble to get access to production facilities.2 Extavia is not a generic or biosimilar drug but simply another branded version of interferon beta-1b made in the same factory. It cost …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.